Oncoscience: Altos Labs and the quest for immortality - Dr. Blagosklonny’s perspective

BUFFALO, NY- May 11, 2022 – A new research perspective was published in Oncoscience journal by Mikhail Blagosklonny, M.D., Ph.D., entitled, “Altos Labs and the quest for immortality: but can we live longer right now?”
 

“Here I discuss how combining rapamycin with other modalities may let us live long enough to benefit from future discoveries in cellular reprogramming and what needs to be done at Altos Labs to make this happen.”
 

Altos Labs—a new anti-aging biotechnology company funded by multiple billionaire investors, including Jeff Bezos and Yuri Milner—has reported a focus on reprogramming cells in order to reverse the trajectory of diseases, and thus, reverse aging.
 

In his research perspective, Dr. Blagosklonny writes that potential life-extension with rapamycin may allow us to win time while awaiting future discoveries that will reverse aging.
 

“Rapamycin treatment is rapidly becoming a mainstream anti-aging intervention.” 
 

However, Dr. Blagosklonny also writes that rapamycin alone is unlikely to extend lifespan sufficiently to benefit from Altos Labs’ future discoveries in our lifetime.
 

“If Altos Labs would allocate a small percentage of its funding to develop rapamycin based drug combinations, then additional decades of life extension may be available 3–5 years from now.”
 

“The number of potential combinations with rapamycin is enormous.” 
 

Read Dr. Blagosklonny’s research perspective: https://www.oncoscience.us/article/552/text/ 

Correspondence to: Mikhail V. Blagosklonny 

Email: Blagosklonny@oncotarget.com, Blagosklonny@rapalogs.com 

Keywords: aging; longevity; lifespan; geroscience; rapalogs; gerostatics

Follow Dr. Blagosklonny on Twitter: https://twitter.com/Blagosklonny

For media inquiries, please contact media@impactjournals.com.

Oncoscience Journal Office
6666 East Quaker Str., Suite 1D
Orchard Park, NY 14127
Phone: 1-800-922-0957, option 4

###